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Abstract
Background: The bacterium Staphylococcus aureus causes significant morbidity and mortality in
humans, primarily due to the emergence of strains that are resistant to antibiotics – notably
methicillin-resistant S. aureus (MRSA) isolates. Development of effective strategies for the control
and treatment of MRSA infections may best be achieved through 'omics' approaches, which first
requires cloning the entire set of S. aureus' protein-encoding open reading frames (ORFs), or
ORFeome.
Results: The complete genome sequence of S. aureus strain Mu50 has 2697 predicted protein-
coding ORFs. Based on the sequence of this strain we designed PCR primers to construct from an
S. aureus (non-MRSA) clinical isolate an ORFeome library that contains 2562 unique Gateway®
entry clones (95% coverage), each corresponding to a defined ORF. The high quality of the
ORFeome library was verified by DNA sequencing and PCR amplification, and its functionality was
demonstrated by expressing recombinant proteins and observing protein interactions in a yeast 2-
hybrid homodimerization screen.
Conclusion:  This first ORFeome library for S. aureus provides an essential new tool for
investigating the systems biology of this important pathogen.
Background
The number of completely sequenced bacterial genomes,
including those of many pathogens, now stands at 640
(revised February 25, 2008) [1]. Such an extensive data-
base provides not only the opportunity to define con-
served open reading frames (ORFs) through a
comparative genomics approach, but also whole-genome
sequence information necessary to construct representa-
tive libraries of cloned ORFs, or 'ORFeomes', to enable
large-scale, high-throughput 'omics' applications. In the
case of hospital- and community-associated methicillin-
resistant Staphyloccocus aureus (MRSA) strains, which are
causing significant morbidity and mortality worldwide [2-
7] the availability of an ORFeome should lead to an
improved understanding of the molecular networks gov-
erning virulence, pathogenesis, and antibiotic resistance
for the control and treatment of S. aureus infection [8-11].
Published: 7 July 2008
BMC Genomics 2008, 9:1321 doi:10.1186/1471-2164-9-321
Received: 14 March 2008
Accepted: 7 July 2008
This article is available from: http://www.biomedcentral.com/1471-2164/9/321
© 2008 Brandner et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Genomics 2008, 9:321 http://www.biomedcentral.com/1471-2164/9/321
Page 2 of 11
(page number not for citation purposes)
The complete genome sequence of S. aureus strain Mu50
[12] encodes 2697 protein-coding ORFs
(gi|47208328|dbj|BA000017.4| [47208328]). The mas-
sive undertaking to clone ORFs by the thousands cannot
be easily achieved by conventional methods using restric-
tion endonucleases. Therefore, we have used the Gateway®
site-specific recombinational cloning system [13] to con-
struct an S. aureus ORFeome library of 2562 unique ORFs
(95% coverage) in 'entry' vectors. Such entry vectors per-
mit ORFs to be easily shuttled into other vector types; for
example, into protein expression vectors to investigate
protein-protein interactions by the yeast 2-hybrid (Y2H)
assay [14]. We verified the quality of our S. aureus ORFe-
ome library by PCR amplification and DNA sequencing.
To demonstrate its functionality, we tested the production
of His-tagged and GST-tagged recombinant proteins in E.
coli. Additionally, we performed a Y2H analysis of 150
randomly chosen S. aureus ORFs to test for protein
homodimerization, a property which is necessary for the
correct functioning of many proteins.
Our repository of S. aureus ORFs offers a highly flexible
platform with which to undertake high-throughput
genomic and proteomic studies of S. aureus and MRSA
infection, including the molecular mechanisms involved
in transmission, virulence, immune-escape, and antibi-
otic resistance.
Results
The overall strategy we have employed for construction
and characterization of the ORFeome of S. aureus is sum-
marized in Figure 1 [see also Additional file 1].
Primer design
In addition to a 20- to 30-nucleotide-long ORF-specific
sequence, each PCR primer was designed to generate a
Gateway®-compatible attB1 (forward primer) or attB2
(reverse primer) recombination site [13,15] flanking the
amplified ORF [see Additional file 2]. Full-length attB
sites at the 5' and 3'ends were generated using secondary
universal adapter primers in the same PCR. A one-step
adapter PCR method was used, instead of the common
two-step adapter PCR procedure, to reduce the required
cloning steps [see Additional file 2]. To allow for the pro-
duction of C-terminal fusion proteins, which can be
expressed from appropriate destination vectors, the stop
codons of each ORF were omitted in the reverse primers.
Shine-Dalgarno (5'-GAAGGAGATA-3') and Kozak (5'-
ACCATG-3') consensus sequences were incorporated into
the forward primers such that the ATG in the Kozak
sequence is in frame with the attB1 site, thus allowing N-
terminal fusion proteins to be produced from destination
vectors that contain N-terminal tags.
Gateway® recombinational cloning
The PCR products were inserted into the Gateway®-com-
patible vector pDONR™/Zeo (Invitrogen) by BP-cloning.
The products resulting from site-specific recombination
were transformed into E. coli. A portion of the cells was
plated on solid medium containing Zeocin™, and the
remainder was used to inoculate liquid medium contain-
ing Zeocin™ to generate bacterial stocks of pooled entry
clones for long-term freezer storage. On solid medium,
~90% of the plates yielded at least 50 colonies; lower
numbers were obtained with inserts >3 kb. A single col-
ony from each plate was tested in a colony-PCR with
pDONR™/Zeo-specific primers. The resulting PCR prod-
ucts were detected by gel electrophoresis and ethidium
bromide staining. Transformants which had an insert of
the expected size were picked and grown in liquid
medium containing Zeocin™ to generate bacterial glycerol
stocks for long-term freezer storage. By this approach we
obtained 1753 transformants carrying the correct insert,
which represents 65% of the 2697 predicted ORFs. Using
both the positive single-colony glycerol stocks to inocu-
late liquid medium containing Zeocin™ and the liquid
glycerol stocks for those ORFs for which no positive sin-
gle-colony isolate was obtained, cultures were grown in
96-well plates and plasmid DNAs were prepared and used
for PCR. For 2562 (95%) samples, an insert of the size
expected for the ORF was observed. The remaining 5%
yielded a PCR product of ~300 bp, derived from empty
pDONR™/Zeo vector. In light of this result, we expect that
additional positive single transformants may be present in
the liquid glycerol stocks. The single-colony glycerol
stocks, the glycerol stocks of the pooled transformants,
and the purified plasmid clones together constitute the
ORFeome of S. aureus.
Validation of entry clones by DNA sequencing
To verify that the inserted ORFs are in the correct reading
frame and indeed correspond to the assigned identity, we
took a random sample of 300 plasmid preparations and
subjected them to sequencing with a pDONR™/Zeo-spe-
cific forward primer. All 300 samples were found to be
correctly inserted, and a BLAST search of each sequence
against the S. aureus Mu50 genome (NCBI Refseq:
NC_002758) confirmed the identity of each ORF.
Validation of entry clones by recombinant protein 
production
Another random sample was used to show expression of
proteins from the cloned ORFs. Forty different entry
clones were each subjected to a recombination reaction,
the LR-Reaction, which recombines the attL-sites on the
entry clones with the attR-sites on the destination vectors
[15]. Twenty of the ORFs were shuttled into the
pDEST™15 vector (Invitrogen) designed to make a fusion
protein with a GST-Tag, and the other 20 entry clonesBMC Genomics 2008, 9:321 http://www.biomedcentral.com/1471-2164/9/321
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were used in an LR-Reaction with the pDEST™17 vector
(Invitrogen), creating fusion proteins with a 6 × His-Tag.
The resulting products were transformed into the
BL21(DE3) protein expression strain of E. coli. After
induction of protein expression with IPTG, the cells were
lysed and 2.5 μg total protein from the crude lysates were
analyzed by Western blot and antibody detection with
biotin-linked anti-His and anti-GST antibodies. Protein
Overview of the construction of the S. aureus ORFeome Figure 1
Overview of the construction of the S. aureus ORFeome. The PCR products of the amplified ORFs were used in the 
first step for a BP reaction, followed by PCR and sequencing for technical confirmation. Finally, generation of a library and vali-
dation by functional analysis were carried out.
Expression VectorsBMC Genomics 2008, 9:321 http://www.biomedcentral.com/1471-2164/9/321
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was expressed from all 20 of the GST-tagged proteins and
17 of the 20 His-tagged proteins (Figure 2).
Yeast two-hybrid homodimerization screen
Numerous proteins must undergo homodimerization
before they can carry out their functions. For example,
many receptors in metabolic pathways are homodimers
or form homodimers after ligand binding. In fact, screen-
ing for new ligands or ligand-competing drugs is some-
times performed by assaying for homodimerization [16].
As a functional test of our S. aureus ORFeome library, we
shuttled 150 entry clones into Gateway®-compatible Y2H
destination vectors to screen for homodimerization in
yeast. After transforming AH109 (Mat a) cells with DNA
binding domain (DB) vectors (pBD-Gate2) and Y187
(Mat α) cells with activation domain (AD) vectors (pAD-
Gate2), colonies growing on each plate were mated on
YPD plates. Yeast colonies appeared on 59 plates deficient
in the reporter supplements adenine and histidine, and in
the vector-encoded amino acids tryptophan and leucine,
indicating 59 putative homodimers (Figure 3). However,
the Y2H system is prone to autoactivation artifacts, in
which a protein expressed from a single vector, rather than
as protein-protein dimer from complementary bait and
prey vectors, is able to reconstitute a functional transcrip-
tion factor to permit growth of the yeast. Therefore, tests
for autoactivation were done to identify such false posi-
tives. For this test, AH109 yeast cells transformed with DB
vectors were plated on nutritionally selective medium
deficient in tryptophan, adenine, and histidine. Y187
yeast cells pre-transformed with AD vectors were mated
with yeast AH109 transformants containing an empty DB
vector and plated on nutritionally selective medium defi-
cient in tryptophan, leucine, adenine, and histidine.
Thirty-seven of the original 59 putative homodimers
failed this test (i.e., colonies were observed); moreover,
the same results were obtained in the added presence of
10 mM 3-amino-1,2,3-triazole (3-AT), a more stringent
growth condition (Figure 3B). We consider the remaining
22 newly discovered homodimerizations to be genuine
protein-protein interactions in S. aureus (Table 1). To
obtain support for this assumption, we searched the liter-
ature for reports of dimerization involving homologs of
these 22 proteins in other species. We found that at least
6 of the 22 proteins have highly conserved dimer-forming
homologs (Table 1), based on biochemical and structural
data.
Discussion
The ORFeome of S. aureus that we constructed in this
work consists of 1753 ORFs maintained as homogeneous
plasmid DNAs purified from single colonies plus 809
Recombinant protein expression in E. coli Figure 2
Recombinant protein expression in E. coli. (A) Western blot of 20 GST-tagged S. aureus recombinant proteins detected 
with anti-GST antibodies. (B) 17 of 20 recombinant His-tagged S. aureus proteins could be detected with anti-His antibodies on 
a Western blot. Equal amounts (2.5 μg) of total protein from crude lysates were loaded in each lane. The arrows indicate the 
recombinant proteins.
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ORFs purified from separate 'pools' of entry clones. These
2562 cloned ORFs represent 95% of the S. aureus (Mu50)
ORFeome, a proportion of coverage similar to those
reported for the ORFeomes of three other bacterial patho-
gens, Brucella melitensis [17], Treponema pallidum [18], and
Francisella tularensis [19]. PCR amplification of the ORFs
produced products not only of the expected size, but also
shorter ones, which were probably primer dimers [20].
Although we did not purify the PCR products as in other
ORFeome projects [21], enough material was produced
for individual BP reactions, all of which resulted in colo-
nies after transformation. Testing of the effectiveness of
both purified and unpurified PCR products in BP reac-
tions showed that cloning could be achieved to the same
extent with both types of PCR products. To minimize the
occurrence of PCR-induced mutations, we optimized the
PCR conditions, used a proofreading-capable DNA
polymerase, and kept the number of amplification cycles
low.
Entry clones are the basis for further experiments using
recombinational cloning, including genome-wide pro-
tein-protein interaction (PPI) analysis, protein expres-
sion, and protein localization studies [22-26]. The single
entry clones are of higher quality than the pools of entry
clones because they are homogeneous, and LR reactions
performed subsequently with the pure clones will be
more efficient. However, for reasons of economy and
because of time constraints, it was not possible to screen
every colony to obtain a pure isolate of the appropriate
ORF-containing entry clone. When the first colony-PCR
failed to produce the anticipated ORF, we screened the
remaining pool of colonies to identify the presence of the
expected entry clone. We failed to produce PCR products
for 135 ORFs. This could be due to possible errors in
annotation of the Mu50 genome or, more likely, because
of nucleotide differences between our clinical S. aureus
isolate and the sequenced Mu50 genome or for technical
reasons related to primer design and effectiveness specific
to each missing ORF.
Different strains of S. aureus can exhibit important differ-
ences in gene content owing to the presence/absence of
plasmids and/or mobile elements integrated into the
chromosome [e.g., staphylococcal cassette chromosome
(SSC) elements, prophage], usually at specific loci termed
"genomic islands" [27]. Such factors are important deter-
minants of MRSA virulence and drug resistance, so that an
ideal ORFeome would include ORFs for these genes in
addition to the bacterial core ORFs. Our ORFeome is cer-
tainly incomplete in this regard, because it is a composite
of only two S. aureus strains; however, ORFs for virulence
and resistance factors of interest could easily be added to
the ORFeome as the resource is further characterized and
developed.
We assessed the quality of the ORFeome by PCR and aga-
rose gel-electrophoresis of the PCR-products for all the
entry clones obtained. Sequencing a sample of 300 PCR
products confirmed the identity of the entry clones. Func-
tional validation was done by recombinant protein pro-
duction and PPI analysis using the Y2H system. In
Table 1: Twenty-two newly described S. aureus homodimers listed by protein size.
Clone Protein name size Interolog
SAV2407 Putative uncharacterized protein 88 AA
SAV1893 Ferritin 166 AA
SAV2249 50S ribosomal protein L4 207 AA
SAV1233 Ribonuclease 3 243 AA [33]
SAV2701 Similar to vraD protein 252 AA
SAV0647 Ferrichrome transport ATP-binding protein 265 AA
SAV2247 50S ribosomal protein L2 277 AA
SAV1330 Homoserine kinase 304 AA [38]
SAV0217 Similar to NADH-dependent dehydrogenase 359 AA
SAV1737 Chorismate mutase homolog 363 AA
SAV1235 Signal recognition particle 416 AA
SAV1627 Similar to ATPase, AAA family 424 AA
SAV1454 Asparaginyl-tRNA synthetase 430 AA [39]
SAV2121 Transcription termination factor Rho 438 AA [40]
SAV1576 Putative 2-methylthioadenine synthetase 448 AA
SAV1900 Glutamyl-tRNA(Gln) amidotransferase subunit A 485 AA
SAV2081 Probable DEAD-box ATP-dependent RNA helicase 506 AA
SAV0205 Oligopeptide transport ATP-binding protein 530 AA
SAV2029 60 kDa chaperonin 538 AA [41]
SAV0700 Fructose specific permease 652 AA
SAV2157 Putative uncharacterized protein 710 AA
SAV1905 ATP-dependent DNA helicase pcrA 730 AA [42]BMC Genomics 2008, 9:321 http://www.biomedcentral.com/1471-2164/9/321
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Y2H screen for homodimers Figure 3
Y2H screen for homodimers. (A) Yeast cells harboring bait and prey plasmids were resuspended in sterile water and 
dropped onto protein interaction selective yeast medium. The positive control shows the interaction of the p53 and SV40-
large T-antigen (Y2H internal controls) and 1 of the 22 found homodimers in this study. A negative interaction obtained in the 
screening is also shown. To test for the presence of both plasmids, the yeast cells were also plated on plasmid-selective 
medium lacking tryptophan and leucine. Y2H positive colonies can grow on synthetic complete yeast media lacking histidine, 
adenine, tryptophan and leucine. (B) Flowchart showing the results of retesting candidate homodimers under stringent selec-
tion conditions. Fifty-nine candidate homodimers were retransformed into AH109 as follows: i) AD-ORFs + DB empty vector; 
ii) DB-ORFs + empty AD vector; and iii) DB-ORFs + AD-ORFs. The transformations were plated on nutritionally selective 
medium deficient for tryptophan, leucine, histidine, and adenine, plus 10 mM 3-AT. All 22 homodimers were confirmed as 
"clean homodimers." The numbers of each type of autoactivator are indicated.
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addition to identifying 22 new homodimeric interactions,
the experiments also showed the functionality of the
ORFeome and its suitability for further applications,
including automated high-throughput protein purifica-
tion or ORFeome-wide PPI analysis. Indeed, generation of
an S. aureus intrapathogen 'interactome' is conceivable
through ORFeome-wide PPI screening of 3.3 million
(2562 × 2562/2) protein-protein interactions by auto-
mated procedures. Likewise, a system-wide screen for
host-pathogen PPIs could be conducted by screening
against other available ORFeomes, e.g. the human ORFe-
ome [28], which would produce a detailed description of
the host-pathogen interface at the molecular level, leading
to improved understanding of S. aureus pathogenesis in
humans.
Production of recombinant proteins in the present system
is achieved with the two well-known protein fusion tags,
6 × His and GST. These tags could be used for further pro-
tein purification or affinity studies such as GST Pull-Down
[29] for validation of protein-protein interactions. We
successfully produced fusion proteins with both types of
tags, although the GST-tagged proteins were more
strongly expressed on average than the His-tagged ones in
our experiments. His-tagged proteins could not be
detected in three out of 20 experiments by Western blot-
ting, due to high background staining caused by the His-
specific antibody used or because of low expression rates,
or both. Although, we loaded equal amounts of total E.
coli protein lysates on protein gels, the intensity of the
expressed proteins varied because of degradation in the
crude cell lysates. It is interesting to note the presence in
some experiments of a second band double the size of the
expected molecular weight, suggesting homodimeriza-
tion, although it is unlikely that dimerization would occur
under the denaturation conditions used.
We tested 150 proteins for homodimerization using the
Y2H-system and found a total of 22 such interactions
(Table 1) after ruling out 37 autoactivators. All Y2H-
experiments, including the autoactivator tests, were per-
formed in triplicate, and each PPI was reproducible by
independent analysis. It is important to stress that even in
the cases of autoactivation, an ORF had to have been
expressed in the yeast reporter strain, which again demon-
strates the functionality of the ORFeome. The 22
homodimers observed here imply that at least ~15% (22
of 150) of the tested proteins can undergo homodimeri-
zation, consistent with the levels found in previous large-
scale studies (2–20%) of different organisms [S. cerevisiae
3.6%, C. elegans 2.8%, D. melanogaster 2.2%, and H. sapi-
ens  19.6% [30]; 143 homodimers among 1546 PPIs
(9.25%, Y2H-dataset) in H. sapiens [31]; 33 homodimers
in 1301 human PPIs (2.5%) [32]. Moreover, in the litera-
ture we found reports of biochemical and/or structural
evidence for homodimerization among homologs (Inter-
ologs) of 6 of our 22 dimer-forming proteins (Table 1).
For example, RNase III, the product of the SAV1233 clone,
is a homodimer in numerous species [33]. In S. aureus,
RNase III is an essential regulator of expression of the spa
gene, which encodes the virulence factor Staphylococcal
protein A[34].
Conclusion
The cloning of 95% of the S. aureus ORFeome was
achieved, and a random sampling of ORF-containing
plasmid vectors showed the ORFs to be functional in two
different downstream applications: recombinant protein
production in E. coli and a protein interaction assay
(Y2H). The availability of the S. aureus ORFeome with
appropriate Gateway®-compatible destination vectors
offers many possibilities for proteome-wide studies of
such medically important phenomena as virulence and
antibiotic resistance in a high-throughput manner. This
first version of the S. aureus ORFeome can be extended in
future work by addition of the missing ORFs.
Methods
Primer Design
The DNA sequence of S. aureus strain Mu50 was obtained
from the NCBI Genome Database (NCBI; Refseq:
NC_002758). Primary gene-specific forward primers were
designed by adding the sequence 5'-AAAAAGCAGGCTT-
GGAAGGAGATAGAACCATG-3' to the 5' end of the first
20 to 30 nucleotides of each ORF. Gene-specific reverse
primers were constructed by adding the nucleotides 5'-
GTACAAGAAAGCTGGGTA-3' to the 5' end of the last 20
to 30 nucleotides of the complementary strand of the
ORF. The gene-specific parts of the primary forward and
reverse primers were chosen to give a similar annealing
temperature during the PCR, between 40–60°C. The 2697
primer pairs were obtained from Illumina Inc. in a 96-well
format.
Isolation and preparation of S. aureus genomic DNA
Genomic DNA of S. aureus was prepared from a fresh
overnight culture of a clinical isolate of S. aureus (non-
MRSA; the strain is sensitive to ampicillin) using the Gen-
Elute™ Bacterial Genomic DNA Kit (Sigma-Aldrich). This
isolate was originally identified as S. aureus by standard
microbiological procedures in a hospital microbiology
laboratory (University Hospital Salzburg). After cell har-
vesting, the pellet was resuspended in resuspension solu-
tion containing 3125 U/μl lysozyme and 62.5 U/ml
lysostaphin and further prepared and purified according
to the product protocol manual. The resulting genomic
DNA had a concentration of 200 ng/μl and a 260/280
absorbance ratio of 1.85.BMC Genomics 2008, 9:321 http://www.biomedcentral.com/1471-2164/9/321
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PCR amplification of the ORFs
Each of the 2697 PCRs were performed in 96-well plates
containing 50-μl assay volumes consisting of 1.25 U Plat-
inum Pfx polymerase (Invitrogen), 1 mM MgSO4, dNTP
mix (0.3 mM each), primary forward and reverse primers
(0.1  μM each), secondary adapter forward and reverse
primers (0.4 μM each), 10× Pfx amplification buffer (5 μl)
and S. aureus genomic DNA (200 ng). The sequence of the
secondary forward adapter primer is 5'-
GGGGACAAGTTTGTACAAAAAAGCAGGCTTG-3' and
that of the secondary reverse adapter primer is 5'-
GGGGACCACTTTGTACAAGAAAGCTGGGTA-3'. After
the first few cycles, enough DNA template was produced
by the primary forward and reverse primers to enable the
secondary adapter primers to bind and extend the first
PCR products to generate the full-length attB1 and attB2
sites flanking the ORFs. All 4 primers were used together
in the same PCR. The 25 PCR cycles (94°C for 30 s, 48°C
for 30 s, and 72°C for 1 min/kb) were preceded by heat-
ing to 94°C for 5 min and were followed by a 7-min incu-
bation at 72°C. PCR products were used immediately
without purification and then stored at -20°C.
attB × attP recombination reactions – BP reactions
The Gateway®-compatible amplified ORFs were recom-
bined into the vector pDONR™/Zeo (Invitrogen) by using
the BP Clonase™ II Enzyme Mix (Invitrogen). In 96-well
plates, samples containing 2 μl unpurified PCR product, 1
μl BP Clonase™ II Enzyme Mix, 150 ng pDONR™/Zeo
plasmid and TE buffer, pH 8.0, up to 10 μl were incubated
overnight at 25°C. After adding 1 μg proteinase K (Invit-
rogen) and incubating at 37°C for 30 minutes, the BP
reactions were directly used for bacterial transformation.
The reactions were stored at -20°C.
Transformation
A 3 μl aliquot from each of the 2697 BP reactions was
added to One Shot® TOP10 chemically competent E. coli
using the manufacturer's protocol and 96-well plates.
After heat-shock at 42°C for 30 s, 50 μl of SOC medium
(Invitrogen) was added to the transformation reactions
and the samples were incubated 1 h at 37°C. After the
incubation, 20 μl of each sample were plated onto low-
salt LB solid medium containing 80 μg/ml Zeocin™ (Inv-
itrogen) and incubated overnight at 37°C to produce sin-
gle colonies. The remainder of the transformation
reaction was used to inoculate 150 μl of low-salt LB liquid
medium containing 80 μg/ml Zeocin™. These cultures
were also incubated at 37°C overnight to generate trans-
formants for long-term storage by adding glycerol and
freezing at -80°C.
Colony PCR of bacterial clones
A single colony from each transformation reaction was
analyzed by PCR to verify the correct size of the inserted
ORF. The 2697 PCRs were performed in 96-well plates
containing 50-μl samples with 2.5 U BioThermRed™
Polymerase (Genxpress), pDONR™/Zeo-specific forward
primer (5'-GTAAAACGACGGCCAG-3') and reverse
primer (5'-CAGGAAACAGCTATGAC-3') (0.3 μM each),
dNTP mix (0.2 mM each) and 10× BioTherm™ reaction
buffer (5 μl). Colonies were picked with a sterile pipet tip
and transferred to the wells of the 96-well plate. The 45
PCR cycles (94°C for 30 s, 55°C for 30 s, and 72°C for 1
min/kb) were preceded by heating to 94°C for 5 min and
followed by a 7-min incubation at 72°C. The sizes of the
PCR products were determined by agarose gel electro-
phoresis and ethidium bromide staining. Entry clones
with inserts having the expected size were inoculated in
150 μl low-salt LB liquid medium containing 80 μg/ml
Zeocin™ and incubated overnight at 37°C to generate
glycerol long-term frozen stocks. In cases where the PCR
failed to verify a positive colony, 'pooled' entry clones
were analyzed. An aliquot of the entire transformation
reaction was cultured in liquid LB medium overnight at
37°C. The entire overnight culture was subject to plasmid
isolation and tested again by PCR. Plasmid preparations
from cultures that were positive by PCR indicated the
presence of correctly cloned ORFs; at worst, they consisted
of a mixed population of cells having empty plasmids and
ORF-containing plasmids.
Glycerol long-term frozen stocks and plasmid preparation
Overnight cultures were mixed with glycerol to a final
glycerol concentration of 40% for long-term storage at -
80°C. One millilitre of low-salt LB liquid medium con-
taining 80 μg/ml Zeocin™ was transferred into 2-ml deep-
well plates (Nunc) and inoculated with 2 μl of overnight
bacterial culture. After overnight growth at 37°C, plas-
mids were purified with a ChargeSwitch® NoSpin Plasmid
Micro Kit (Invitrogen) in a 96-well plate format.
DNA sequencing
Sequencing of plasmid DNAs was performed on 300 ran-
domly chosen PCR-positive ORFs. Standard dideoxy
sequencing was used [35,36]. A 10-μl sample containing
5 μl plasmid preparation, the same pDONR™/Zeo forward
primer as above (0.32 μM), 2 μl BigDye® Terminator v3.1
Ready Reaction Mix (Applied Biosystems) and 1 μl 5×
sequencing buffer was heated to 95°C for 5 min followed
by 25 cycles of extension reactions (95°C for 10 s, 50°C
for 5 s, and 60°C for 90 s). After precipitating with
sodium acetate and absolute ethanol, the redissolved
DNA was sequenced with an ABI 3130 Genetic Analyzer
Capillary Array (Applied Biosystems).
attL × attR recombination reactions – LR reactions
Entry vectors were set up in LR reactions to recombine the
gene of interest into several destination vectors. The desti-
nation vectors used were pDEST™15, pDEST™17 (bothBMC Genomics 2008, 9:321 http://www.biomedcentral.com/1471-2164/9/321
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from Invitrogen), pBD-Gate 2, and pAD-Gate 2 [37]. The
two Gate vectors are in-house-generated Gateway®-com-
patible pGADT7 and pGBKT7 plasmids of the Match-
maker™ GAL4 Two-Hybrid system (Clontech) for yeast
two-hybrid analysis. Samples containing 5 μl prepared
entry clone, 1 μl LR Clonase™ II Enzyme Mix (Invitrogen),
destination vector (150 ng), and TE buffer, pH 8.0, to 10
μl were incubated at 25°C for two hours. After adding 1
μg proteinase K (Invitrogen) and incubating at 37°C for
30 min, the LR reactions were directly used for plasmid
transformation into E. coli. The reactions were stored at -
20°C. Bacteria were transformed with the LR reactions as
described above using the appropriate antibiotic: 100 μg/
ml ampicillin for pDEST™15, 17, and pAD-Gate2; and 50
μg/ml kanamycin for pBD-Gate2. Colony PCRs were per-
formed as described above to verify the successful cloning
by using vector-specific primers. The expression clones
were prepared using a Plasmid Purification NoSpin Plas-
mid Micro Kit (Invitrogen).
Recombinant protein production
Prepared pDEST™15 and 17 expression vectors, which
harbor the desired ORFs, were transformed into chemi-
cally competent E. coli BL21(DE3) (Invitrogen) and
plated onto LB solid medium containing 100 μg/ml amp-
icillin. Single colonies from each plate were used to inoc-
ulate 3 ml LB liquid medium containing 100 μg/ml
ampicillin. Cells were grown at 37°C until the OD600
reached 0.4–0.6, and protein expression was induced by
adding IPTG (0.5 mM) and incubating for a further two
hours. The cells were lysed and protein expression was
shown by SDS-PAGE and Western blot analysis with anti-
body detection.
Western blot analysis
Proteins were denatured at 95°C for 5 min and separated
on a gel (NuPAGE® 10% Bis-Tris Gels (Invitrogen)) at 165
V for 90 min. Buffers used were from Invitrogen
(NuPAGE® SDS running buffer, and LDS sample buffer).
Proteins were electroblotted onto a Hybond-ECL™ nitro-
cellulose membrane (Amersham Biosciences) with blot-
ting buffer (3 g Tris, 14.4 g glycine, 200 ml methanol, 10
ml 10% SDS in 1000 ml water, pH 8.4) at 60 V for 1 h.
Membranes were blocked with 5% BSA (Calbiochem, San
Diego, CA) in TBS + 0.3% Tween-20® (Sigma-Aldrich) pH
7.4, at room temperature for 1 h, followed by incubation
with first antibodies for 1 h. Two 5-min washing steps
with TBS were followed by incubation with secondary
antibodies for 1 h. After four final washing steps with TBS
(10 min each), Western-blue stabilized substrate alkaline
phosphatase (Promega) was added. Primary antibodies:
Mouse anti-GST (B-14): sc-138 B and mouse anti-His His-
probe (H-3): sc-8036 B (Santa Cruz Biotechnology, Santa
Cruz, CA); both antibodies are biotin conjugates. Second-
ary antibodies: anti-mouse IgG – alkaline phosphatase-
conjugated (Sigma-Aldrich).
Yeast 2-hybrid analysis – yeast transformation and mating
Prepared expression vectors containing the desired ORFs
were transformed into the yeast strains AH109 (Mat a)
and Y187 (Mat α) (both Clontech) and first plated on a
nutritionally selective plate deficient in tryptophan for
pBD-Gate2 transformants and deficient in leucine for
pAD-Gate2 transformants. One hundred and fifty baits
(pBD-Gate2 Y2H expression vectors harboring the bacte-
rial ORFs) were transformed into AH109 (Mat a) and 150
preys (pAD-Gate2 Y2H expression vectors harboring the
bacterial ORFs) were transformed into Y187. After incuba-
tion for 5 days at 28°C, up to 5 colonies from each trans-
formation reaction were used to inoculate the
corresponding liquid medium and incubated at 28°C
until the cultures reached turbidity. Additionally, glycerol
stocks were prepared for long-term storage by adding an
equal volume of 100% glycerol to the liquid cultures. For
the mating procedure, 5 μl of liquid cultures of bait and
prey of opposite mating type were brought together on a
YPD plate and incubated overnight at 28°C. The next day
a small amount of cell material was dissolved in 100 μl of
autoclaved distilled water and one-half of each was plated
onto a nutritionally selective plate deficient in tryptophan
and leucine to test for positive mating and on a nutrition-
ally selective plate deficient in tryptophan, leucine, ade-
nine, and histidine to test for the putative interaction.
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